US7811572B2
(en)
|
2005-08-24 |
2010-10-12 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
EP2185544B1
(fr)
|
2007-07-19 |
2014-11-26 |
Cymabay Therapeutics, Inc. |
Derives subtitues heterocycliques a liaison n de pyrrole, pyrazole, imidazole, triazole et tetrazole comme agonistes de recepteurs rup3 ou gpr119 utilises dans le traitement du diabete et des troubles metaboliques
|
DE102008056086A1
(de)
*
|
2008-11-06 |
2010-05-12 |
Gp Solar Gmbh |
Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung
|
IL295601B1
(en)
|
2009-02-05 |
2024-07-01 |
Immunogen Inc |
History of benzodiazepines and processes for their preparation
|
AU2015224492B2
(en)
*
|
2009-02-05 |
2017-04-20 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
MX349210B
(es)
|
2009-06-03 |
2017-07-18 |
Immunogen Inc |
Métodos de conjugación.
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
FR2949469A1
(fr)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
CN102666553B
(zh)
|
2009-10-01 |
2015-05-06 |
赛马拜制药公司 |
取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
|
CN105001334A
(zh)
|
2010-02-10 |
2015-10-28 |
伊缪诺金公司 |
Cd20抗体及其用途
|
US20110256157A1
(en)
*
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
CN107019804A
(zh)
|
2010-04-15 |
2017-08-08 |
西雅图基因公司 |
靶向吡咯并苯并二氮杂卓结合物
|
CN102971329B
(zh)
|
2010-04-15 |
2016-06-29 |
麦迪穆有限责任公司 |
用于治疗增殖性疾病的吡咯并苯并二氮杂卓
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
FR2963007B1
(fr)
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
BR112013020540B1
(pt)
|
2011-02-15 |
2020-12-29 |
Immunogen, Inc |
métodos para preparação de conjugados compreendendo agente de ligação à célula conjugado a composto citotóxico com grupo ligante
|
AU2012236398B2
(en)
|
2011-03-29 |
2016-02-11 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
US9156854B2
(en)
|
2011-04-18 |
2015-10-13 |
Immunogen, Inc. |
Maytansinoid derivatives with sulfoxide linker
|
CA2849039C
(fr)
|
2011-09-20 |
2018-09-18 |
Spirogen Sarl |
Pyrrolobenzodiazepines comme composes dimeres de pbd asymetriques pour inclusion dans des conjugues cibles
|
WO2013053871A1
(fr)
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Pyrrolobenzodiazépines
|
US9387259B2
(en)
|
2011-10-14 |
2016-07-12 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
EP2755642B1
(fr)
|
2011-10-14 |
2018-07-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazépines et conjugués ciblés
|
JP6170497B2
(ja)
|
2011-10-14 |
2017-07-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン
|
SG11201403179QA
(en)
*
|
2011-12-13 |
2014-07-30 |
Immunogen Inc |
Use of n-hydroxysuccinimide to improve conjugate stability
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
BR112014027166A2
(pt)
|
2012-05-01 |
2017-06-27 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
|
WO2013177481A1
(fr)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazépines et leurs conjugués
|
BR112015000441A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
|
BR112015000437A2
(pt)
|
2012-07-09 |
2017-06-27 |
Genentech Inc |
imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
|
MX2015001399A
(es)
|
2012-08-02 |
2015-09-07 |
Genentech Inc |
Anticuerpos anti-etbr e inmunoconjugados.
|
EP2887965A1
(fr)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
WO2014055877A1
(fr)
*
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Utilisation d'une membrane de pvdf pour purifier des conjugués d'agent de liaison cellulaire-agent cytotoxique
|
JP6270859B2
(ja)
|
2012-10-12 |
2018-01-31 |
エイディーシー・セラピューティクス・エス・アー・エール・エルAdc Therapeutics Sarl |
ピロロベンゾジアゼピン−抗体結合体
|
US9745303B2
(en)
|
2012-10-12 |
2017-08-29 |
Medimmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
CN105102068B
(zh)
|
2012-10-12 |
2018-06-01 |
Adc疗法责任有限公司 |
吡咯并苯并二氮杂卓-抗体结合物
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
AU2013328674B2
(en)
|
2012-10-12 |
2017-06-22 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2906250B1
(fr)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Conjugués pyrrolobenzodiazepine-anticorps anti-psma
|
WO2014057120A1
(fr)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Conjugués anticorps - pyrrolobenzodiazépine
|
ES2703151T3
(es)
|
2012-10-12 |
2019-03-07 |
Adc Therapeutics Sa |
Conjugados de anticuerpos de pirrolobenzodiazepinas
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
WO2014140862A2
(fr)
|
2013-03-13 |
2014-09-18 |
Spirogen Sarl |
Pyrrolobenzodiazépines et leurs conjugués
|
EP2968494B1
(fr)
|
2013-03-13 |
2018-11-14 |
Seattle Genetics, Inc. |
Filtration par charbon actif pour la purification d'adc de benzodiazépine
|
BR112015023070B1
(pt)
*
|
2013-03-13 |
2022-06-07 |
Genentech, Inc. |
Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP2970474B1
(fr)
|
2013-03-14 |
2017-12-20 |
Genentech, Inc. |
Anticorps et immunoconjugués anti-b7-h4
|
TWI636792B
(zh)
|
2013-08-12 |
2018-10-01 |
建南德克公司 |
1-(氯甲基)-2,3-二氫-1h-苯并[e]吲哚二聚體抗體-藥物結合物化合物及使用與治療方法
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
WO2015052534A1
(fr)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Conjugués anticorps-pyrrolobenzodiazépine
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
CA2931340A1
(fr)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anticorps et immunoconjugues anti-cd33
|
MX2016007578A
(es)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
|
JP6417421B2
(ja)
|
2014-02-28 |
2018-11-07 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
荷電連結体及び共役体のためのその使用
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
MX2017002605A
(es)
|
2014-08-28 |
2017-05-19 |
Bioatla Llc |
Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
|
TW201613930A
(en)
|
2014-09-03 |
2016-04-16 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
DK3189056T3
(da)
|
2014-09-03 |
2020-09-14 |
Immunogen Inc |
Cytotoksiske benzodiazepinderivater
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
KR102508173B1
(ko)
|
2014-09-12 |
2023-03-10 |
제넨테크, 인크. |
항-her2 항체 및 면역콘주게이트
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
TW201625688A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
經半胱胺酸改造之抗體及接合物
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CA2957148A1
(fr)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugues comprenant des anticorps anti-her2 et des pyrrolobenzodiazepines
|
EP3223854A1
(fr)
|
2014-11-25 |
2017-10-04 |
ADC Therapeutics SA |
Conjugués anticorps-pyrrolobenzodiazépine
|
BR112017014937A2
(pt)
|
2015-01-14 |
2018-03-13 |
Bristol-Myers Squibb Company |
dímeros de benzodiazepina ligados em ponte a heteroarileno, conjugados dos mesmos, e métodos de preparação e uso
|
BR112017014599A2
(pt)
|
2015-01-14 |
2018-01-16 |
Bristol-Myers Squibb Company |
dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
MX2017015814A
(es)
|
2015-06-23 |
2018-04-10 |
Squibb Bristol Myers Co |
Dimeros de benzodiazepina macrociclica, conjugados de los mismos, preparacion y usos.
|
CN113350518A
(zh)
|
2015-07-12 |
2021-09-07 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
HUE051541T2
(hu)
|
2015-07-21 |
2021-03-01 |
Immunogen Inc |
Eljárások citotoxikus benzodiazepin származékok elõállítására
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
CN107405408B
(zh)
*
|
2015-12-21 |
2021-07-02 |
江苏恒瑞医药股份有限公司 |
一种抗体药物偶联物的制备方法
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
KR102606938B1
(ko)
|
2016-04-15 |
2023-11-29 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(fr)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux
|
AU2017263568B2
(en)
|
2016-05-13 |
2024-01-18 |
Bioatla, Llc |
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
CN107469089B
(zh)
*
|
2016-06-07 |
2022-01-07 |
北京键凯科技股份有限公司 |
一种peg连接子及配基药物偶联物
|
WO2017214182A1
(fr)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
AU2017305392A1
(en)
|
2016-08-03 |
2019-02-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
WO2018031662A1
(fr)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
EP3538080A4
(fr)
|
2016-11-14 |
2020-07-08 |
Hangzhou Dac Biotech Co., Ltd. |
Lieurs de conjugaison, conjugués médicament-molécule de liaison à une cellule contenant lesdits lieurs, procédés de préparation et d'utilisation de tels conjugués avec les lieurs
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
CA3044391A1
(fr)
|
2016-11-23 |
2018-05-31 |
Immunogen, Inc. |
Sulfonation selective de derives de benzodiazepine
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
US20210388102A1
(en)
|
2016-12-23 |
2021-12-16 |
Immunogen, Inc. |
Immunoconjugates targeting adam9 and methods of use thereof
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
ES2871001T3
(es)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
RS63502B1
(sr)
|
2017-04-18 |
2022-09-30 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
US20180346488A1
(en)
|
2017-04-20 |
2018-12-06 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
AU2018268970A1
(en)
|
2017-05-19 |
2019-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
US11318211B2
(en)
|
2017-06-14 |
2022-05-03 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
WO2019005208A1
(fr)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse
|
CA3066953A1
(fr)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Anticorps monoclonaux humains specifiques de cd33 et leurs procedes d'utilisation
|
DK3668874T3
(da)
|
2017-08-18 |
2022-02-14 |
Medimmune Ltd |
Pyrrolobenzodiazepin-konjugater
|
IL301637B1
(en)
|
2017-09-29 |
2024-06-01 |
Daiichi Sankyo Co Ltd |
Conjugation of an antibody with a pyrrolobenzodiazepine derivative
|
US11793885B2
(en)
|
2017-12-28 |
2023-10-24 |
Immunogen, Inc. |
Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
WO2020033430A1
(fr)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonaux à haute affinité ciblant le glypicane-2 et leurs utilisations
|
TW202029980A
(zh)
|
2018-10-26 |
2020-08-16 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
EP3898693A4
(fr)
|
2018-12-21 |
2022-09-21 |
Avidity Biosciences, Inc. |
Anticorps anti-récepteurs de transferrine et utilisations associées
|
US20220096641A1
(en)
*
|
2019-01-03 |
2022-03-31 |
Legochem Biosciences, Inc. |
Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
|
CN113490510A
(zh)
|
2019-01-08 |
2021-10-08 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
|
US20220098323A1
(en)
|
2019-01-22 |
2022-03-31 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
WO2020160156A2
(fr)
|
2019-01-30 |
2020-08-06 |
Immutics, Inc. |
Anticorps anti-gal3 et leurs utilisations
|
JP2022529583A
(ja)
|
2019-03-29 |
2022-06-23 |
イミュノジェン・インコーポレーテッド |
異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス-ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体
|
JP2022552875A
(ja)
|
2019-10-22 |
2022-12-20 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ
|
EP4041769A1
(fr)
|
2019-12-12 |
2022-08-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Conjugués anticorps-médicament spécifiques à cd276 et leurs utilisations
|
WO2021188390A1
(fr)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions et méthodes de traitement d'une dystrophie musculaire facio-scapulo-humérale
|
IL296393A
(en)
|
2020-03-27 |
2022-11-01 |
Avidity Biosciences Inc |
Preparations and methods for the treatment of muscle atrophy
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
WO2022232612A1
(fr)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nanocorps spécifiques du virus de lassa et leurs méthodes d'utilisation
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
WO2023288252A1
(fr)
|
2021-07-13 |
2023-01-19 |
Truebinding, Inc. |
Méthodes de prévention de l'agrégation de protéines
|
CA3231330A1
(fr)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions et methodes de traitement d'une dystrophie musculaire facio-scapulo-humerale
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|